Envista Holdings Co. (NYSE:NVST) Given Average Rating of "Hold" by Analysts

Envista Holdings Co. (NYSE:NVST - Get Free Report) has received a consensus recommendation of "Hold" from the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $20.13.

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus increased their price objective on Envista from $18.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday, October 23rd. Piper Sandler raised their price target on Envista from $16.00 to $17.00 and gave the company a "neutral" rating in a report on Thursday, October 31st. Robert W. Baird lifted their price target on Envista from $17.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday, October 31st. Leerink Partnrs upgraded shares of Envista from a "strong sell" rating to a "hold" rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company initiated coverage on shares of Envista in a research report on Tuesday, October 8th. They set an "equal weight" rating and a $20.00 target price for the company.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in NVST. Iron Triangle Partners LP purchased a new stake in Envista in the 3rd quarter worth approximately $43,262,000. Point72 Asset Management L.P. purchased a new stake in Envista in the third quarter worth $37,559,000. Polar Asset Management Partners Inc. lifted its stake in Envista by 375.6% in the third quarter. Polar Asset Management Partners Inc. now owns 1,497,250 shares of the company's stock worth $29,586,000 after acquiring an additional 1,182,450 shares during the period. Ariel Investments LLC boosted its holdings in Envista by 11.0% in the second quarter. Ariel Investments LLC now owns 9,871,152 shares of the company's stock valued at $164,157,000 after acquiring an additional 978,952 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in Envista by 26.5% during the 3rd quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company's stock valued at $78,480,000 after purchasing an additional 830,861 shares during the period.

Envista Price Performance

Shares of NVST traded up $0.14 during midday trading on Friday, hitting $21.44. 1,959,871 shares of the company traded hands, compared to its average volume of 1,863,444. Envista has a one year low of $15.15 and a one year high of $24.79. The firm has a market cap of $3.69 billion, a P/E ratio of -2.76, a PEG ratio of 1.88 and a beta of 1.33. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The stock has a 50-day moving average of $20.01 and a 200-day moving average of $18.80.

Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The business had revenue of $601.00 million for the quarter, compared to analyst estimates of $590.34 million. During the same quarter in the prior year, the firm posted $0.43 EPS. Envista's revenue was down 4.8% on a year-over-year basis. As a group, sell-side analysts predict that Envista will post 0.72 EPS for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.